|
|
|
|
Direct Cost |
Indirect Cost |
|
1F32CA200265-01A1 |
Hybrid Glycoproteomic and Autoantibody Biomarkers for Lung Cancer Early Detection |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$56,058 |
|
$56,058 |
1F32DA041100-01A1 |
Development of a Targeted, Web-Based Intervention for Smokers with Social Anxiety Disorder Using Acceptance and Commitment Therapy |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIDA |
$58,794 |
|
$58,794 |
1K22CA193860-01 |
PCOS, Type II diabetes and ovarian cancer risk |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$170,940 |
$13,675 |
$184,615 |
1K22CA201229-01 |
Frizzled2 Signaling in Metastatic Cancers |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$166,417 |
$13,313 |
$179,730 |
1K99AI125136-01A1 |
Host Innate Immune Response as a Barrier to Cross-Species Retrovirus Transmission |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$89,850 |
$7,188 |
$97,038 |
1R01AI120961-01A1 |
DEFINING THE INFANT IMMUNE RESPONSE TO HIV |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$474,182 |
$313,085 |
$787,267 |
1R01AI121129-01A1 |
Immunoprotective Properties of Tissue-resident Memory T Cells in Mice and Humans within Mucosal Sites |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$541,314 |
$315,207 |
$856,521 |
1R01AI121242-01A1 |
TCR-like antibodies for HPV-induced cancer basic research and theranostics |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$251,280 |
$190,973 |
$442,253 |
1R01AI122912-01A1 |
Identification and Analysis of HIV-specific Naive B cells in HIV-unexposed Individuals |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$315,377 |
$239,687 |
$555,064 |
1R01AI122991-01A1 |
Statistical methods for HIV-1 immune correlates studies |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$179,466 |
$136,394 |
$315,860 |
1R01AI127100-01 |
Role of the microbiome in HIV vaccine induced heterogeneity |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$435,555 |
$331,022 |
$766,577 |
1R01AI127893-01 |
High-throughput experiments to guide influenza vaccine strain selection |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$251,760 |
$191,338 |
$443,098 |
1R01CA190661-01A1 |
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$327,366 |
$248,799 |
$576,165 |
1R01CA192222-01A1 |
Human and Bacterial Molecular Pathways in Cancer Risk: Modulation by Diet |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$427,654 |
$316,128 |
$743,782 |
1R01CA193808-01A1 |
CDK2 and Cancer: Mechanisms and Opportunities |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$246,521 |
$182,294 |
$428,815 |
1R01CA195718-01A1 |
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$373,500 |
$283,860 |
$657,360 |
1R01CA195789-01A1 |
Statistical Methods for Genetic Epidemiology Studies |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$228,750 |
$173,850 |
$402,600 |
1R01CA201407-01A1 |
Using functional genomics to inform gene environment interactions for colorectal cancer |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$1,553,622 |
$507,355 |
$2,060,977 |
1R01CA206462-01A1 |
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$325,735 |
$247,558 |
$573,293 |
1R01DC015032-01 |
Mechanisms Underlying Innate Odor Fear |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIDCD |
$212,500 |
$161,500 |
$374,000 |